|
|
The goal of the NIDDK-sponsored Diabetic Complications Consortium (DCC) is to provide an environment that will foster communication and collaboration between investigator communities involved in complications research. Toward this goal, the DCC will:
DCC Preclinical Testing Program 2012-2013PROGRAM DESCRIPTION: T1D-RAID and NIH-RAID are cooperative programs designed to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions. However, in some cases, additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before new therapeutics can progress along the drug development pipeline.In recognition of the compelling need to develop new therapeutics for several diabetic complications, the DCC has established a Preclinical Testing Program (DCC-PTP). The DCC-PTP will provide investigators with access to pilot funds to pursue additional preclinical studies of promising new therapeutics. The T1D-RAID and DCC-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for complications of Type 1 Diabetes. The common goal of these programs is to support the preclinical work necessary to obtain "proof of principle" establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation. The DCC is currently soliciting P&F proposals from investigators with promising new therapeutics for diabetic complications, to support expanded preclinical efficacy studies.
For instructions on how to submit a Preclinical Testing Funding Program Application to the DCC web portal please click the following link: Funding Program Application Submission Basic Training (PDF) |
| Budget requests should be commensurate with project needs over a one year project period. Average DCC–PTP awards range between $50,000-$60,000 Total Costs for one year. |
| Each submitted proposal will be assigned to three reviewers who are either members of the DCC External Evaluation Committee or external scientists with expertise in the area of a proposal. Reviewers may be at an institution affiliated with the DCC, but should not serve as a member of the DCC steering committee (please see www.diacomp.org). Scientists from institutions submitting a proposal are in conflict and excluded from review. Final funding decisions will be made by the NIH. |
|
There is no formal deadline associated with Preclinical applications, but applications
will be reviewed quarterly (March 1, June 1, September 1, December 1) and
so should be submitted accordingly.
The brief application should be on the PHS 398 form, and must be composed of a research plan that includes the following sections: A. Abstract and Specific Aims, B. Background and Significance, C. Preliminary Studies, D. Research Design and Methods, E. Explicit description of the collaboration and contributions of the collaborating investigators. In the case of Pilot and Feasibility projects, this section should include a brief description of how the test will be made available to DCC users, F. Signed letters from any collaborating principal investigators that have not signed the application face page. G. Literature Cited. H. Detailed Budget. I. Vertebrate Animals (Sections A->E are limited to 5 pages). Applications should be signed by at least one principal investigator and an official representing the submitting institution. NOTE: Applicants should submit one (1) paper copy to the DCC CBU at the address listed below, plus submit an electronic version of the application via the DCC website (PDF format only please). Eligible Organizations: Public or private institutions in the United States, such as universities, colleges, hospitals, and laboratories; units of state and local governments; eligible agencies of the Federal government; faith-based or community-based organizations; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); and Indian/Native American Tribally Designated Organization. Eligible Project Directors/Principal Investigators: In the collaborative spirit of the Preclinical awards, each application must include at least two project directors/principal investigators, one of whom must be an DCC investigator. The application may originate from either the DCC or the collaborating institution. Applicants must hold a doctoral level position but young investigators and post-doctoral fellows are encouraged to apply. Applications from post-doctoral fellows or research staff must include two letters of recommendation. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. |
| A progress report is due two months following the completion of the 1 year funding period. If competitive renewal is sought, the application should be received for the review cycle prior to end of the projects current funding period. Application for competitive renewal is not in lieu of a year-end progress report. As part of the progress report, awarded applicants will be expected to deposit data, protocols and resources relevant to their proposal to the Diabetic Complications Consortium website. |
|
Richard McIndoe, Ph.D. (Coordinator)
Coordinating and Bioinformatics Unit
Georgia Health Sciences University
Center for Biotechnology and Genomic Medicine
1120 15th Street, CA4124
Augusta, GA 30912-4810
Phone: 706-721-3542
Fax: 706-721-3688
|
|
|